US Pharma MarketingDisc Medicine
Shionogi Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
Plus news about Tevard Biosciences, InduPro, EMD Serono, Shionogi, Bayer's Hyrnuo.
Disc's competitor for Takeda's blood disorder drug Mimrylo: Disc Medicine shared initial data from its Phase 2 RESTORE-PV trial, which ...
Source: Endpoints News